{"result": "{\n    \"title\": \"Eli Lilly and DrotAA: A Study in Septic Shock Treatment\",\n    \"summary\": \"This report focuses on the network surrounding Eli Lilly, a pharmaceutical company, and its drug DrotAA (Xigris), particularly in relation to the PROWESS-SHOCK clinical trial. The entities involved include regulatory bodies like the European Medicines Agency and the Food and Drug Administration, as well as research institutions such as the Duke Clinical Research Institute. The relationships and activities of these entities provide insight into the drug's development, regulatory approval, and the scientific scrutiny it has undergone.\",\n    \"rating\": 7.5,\n    \"rating_explanation\": \"The impact severity rating is high due to the critical nature of the drug's intended use in life-threatening conditions and the involvement of major regulatory bodies.\",\n    \"findings\": [\n        {\n            \"summary\": \"Eli Lilly's pivotal role in DrotAA's development and study\",\n            \"explanation\": \"Eli Lilly, a major pharmaceutical company, has been instrumental in the development and study of DrotAA (Xigris), a drug intended for the treatment of septic shock. The company's commitment to advancing medical treatments is evident through its funding of the PROWESS-SHOCK trial, which aimed to assess the drug's efficacy in reducing mortality rates among septic shock patients. This relationship underscores the company's influence in the pharmaceutical and healthcare sectors, highlighting its role in pushing the boundaries of medical science. [Data: Entities (1), Relationships (10, 6)]\"\n        },\n        {\n            \"summary\": \"Regulatory scrutiny by the European Medicines Agency and the FDA\",\n            \"explanation\": \"The European Medicines Agency and the Food and Drug Administration have played critical roles in the regulatory oversight of DrotAA. The EMA granted marketing authorization for the drug, subject to annual review, reflecting the cautious optimism surrounding its potential benefits. Conversely, the FDA's decision to limit approval for use in high-risk patients and request additional trials underscores the complexities and challenges in assessing drug efficacy and safety. These regulatory actions highlight the rigorous scrutiny drugs must undergo before and after reaching the market. [Data: Entities (3, 4), Relationships (2, 3)]\"\n        },\n        {\n            \"summary\": \"The PROWESS-SHOCK trial's impact on medical research\",\n            \"explanation\": \"The PROWESS-SHOCK trial, comparing DrotAA with a placebo in patients with septic shock, represents a significant effort in medical research to improve patient outcomes in critical care. The trial's focus on mortality rates among a high-risk patient population underscores the urgent need for effective treatments in septic shock management. The involvement of the Duke Clinical Research Institute in analyzing the study further emphasizes the collaborative effort between pharmaceutical companies and research institutions in advancing medical knowledge and patient care. [Data: Entities (2, 8), Relationships (1, 11)]\"\n        },\n        {\n            \"summary\": \"Use of APACHE II and SOFA scores in clinical studies\",\n            \"explanation\": \"The application of APACHE II and SOFA scores in the Eli Lilly-sponsored study illustrates the importance of standardized measures in assessing drug efficacy. These scoring systems, used to measure the severity of disease in critically ill patients, provide a framework for evaluating the impact of treatments like DrotAA on organ dysfunction and mortality. The use of these scores in clinical trials underscores the scientific rigor applied in studying the drug's effects, contributing to a better understanding of its potential benefits and limitations. [Data: Relationships (9, 8)]\"\n        },\n        {\n            \"summary\": \"Collaboration between Eli Lilly and Duke Clinical Research Institute\",\n            \"explanation\": \"The partnership between Eli Lilly and the Duke Clinical Research Institute for the analysis of the PROWESS-SHOCK study highlights the importance of collaboration between the pharmaceutical industry and academic research institutions. This collaboration not only facilitates the rigorous evaluation of new medical treatments but also bridges the gap between drug development and clinical application. Such partnerships are crucial in advancing medical science and improving patient outcomes through evidence-based research. [Data: Relationships (7)]\"\n        }\n    ]\n}", "input": "\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community's key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    \"title\": \"Verdant Oasis Plaza and Unity March\",\n    \"summary\": \"The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.\",\n    \"rating\": 5.0,\n    \"rating_explanation\": \"The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.\",\n    \"findings\": [\n        {{\n            \"summary\": \"Verdant Oasis Plaza as the central location\",\n            \"explanation\": \"Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza's association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]\"\n        }},\n        {{\n            \"summary\": \"Harmony Assembly's role in the community\",\n            \"explanation\": \"Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]\"\n        }},\n        {{\n            \"summary\": \"Unity March as a significant event\",\n            \"explanation\": \"The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community's dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]\"\n        }},\n        {{\n            \"summary\": \"Role of Tribune Spotlight\",\n            \"explanation\": \"Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]\"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\n2,PROWESS-SHOCK,A clinical trial comparing DrotAA with placebo in patients with septic shock to assess mortality rates,2\n1,ELI LILLY,\"Eli Lilly is a pharmaceutical company based in Indianapolis, known for producing drotrecogin alfa activated, also known as DrotAA or Xigris. This company has been actively involved in clinical studies to evaluate the drug's impact on patients with specific health conditions, notably funding the PROWESS-SHOCK trial for DrotAA. Through its commitment to research and development in the pharmaceutical field, Eli Lilly has established itself as a key player in advancing medical treatments and therapies.\",6\n7,\"DROTRAA (XIGRIS, ELI LILLY)\",\"DrotAA (Xigris, Eli Lilly) is a drug administered as an intravenous infusion at a dose of 24 μg per kilogram of body weight per hour for 96 hours in a study to assess its efficacy in patients\",1\n3,EUROPEAN MEDICINES AGENCY,\"Regulatory body that granted marketing authorization for DrotAA for severe sepsis and multiple organ failure, subject to annual review\",1\n4,FOOD AND DRUG ADMINISTRATION,US regulatory agency that limited DrotAA's approval for use in patients with a high risk of death and requested additional trials,1\n6,PROWESS,No Description,1\n8,DUKE CLINICAL RESEARCH INSTITUTE,\"The Duke Clinical Research Institute performed the analysis for the study involving DrotAA (Xigris, Eli Lilly)\",1\n10,SEQUENTIAL ORGAN FAILURE ASSESSMENT (SOFA) SCORES,No Description,1\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,combined_degree\n5,DROTRECOGIN ALFA (ACTIVATED) OR DROTAA,SEPTIC SHOCK,DrotAA was investigated for its efficacy in treating septic shock in the PROWESS-SHOCK trial,83\n11,PROWESS-SHOCK,SEPTIC SHOCK,The PROWESS-SHOCK trial focused on patients with septic shock to assess the efficacy of DrotAA,79\n10,ELI LILLY,DROTRECOGIN ALFA (ACTIVATED),Eli Lilly is the producer of drotrecogin alfa activated,13\n9,ELI LILLY,APACHE II SCORE,APACHE II score was used as a baseline characteristic in the Eli Lilly-sponsored study to examine the treatment effect on mortality,10\n1,DROTRECOGIN ALFA (ACTIVATED) OR DROTAA,PROWESS-SHOCK,DrotAA was the subject of the PROWESS-SHOCK trial to test its efficacy in reducing mortality in septic shock patients,8\n6,ELI LILLY,\"DROTRAA (XIGRIS, ELI LILLY)\",\"DrotAA (Xigris) is a product of Eli Lilly, indicating a direct product-company relationship\",7\n2,DROTRECOGIN ALFA (ACTIVATED) OR DROTAA,EUROPEAN MEDICINES AGENCY,\"The European Medicines Agency granted marketing authorization for DrotAA, subject to annual review\",7\n3,DROTRECOGIN ALFA (ACTIVATED) OR DROTAA,FOOD AND DRUG ADMINISTRATION,The FDA limited DrotAA's approval for use in patients with a high risk of death,7\n4,DROTRECOGIN ALFA (ACTIVATED) OR DROTAA,PROWESS,The PROWESS study was crucial in the initial approval of DrotAA for the treatment of severe sepsis,7\n7,ELI LILLY,DUKE CLINICAL RESEARCH INSTITUTE,\"The Duke Clinical Research Institute conducted the analysis for the study sponsored by Eli Lilly, indicating a collaboration between the institute and the company\",7\n8,ELI LILLY,SEQUENTIAL ORGAN FAILURE ASSESSMENT (SOFA) SCORES,SOFA scores were used in the study sponsored by Eli Lilly to measure organ dysfunction and assess the efficacy of DrotAA,7\n\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:", "parameters": {"model": "gpt-4-turbo-preview", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 2000, "n": 1}, "history": null}